Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY22 results · Apr–Jun 2021
Sun Pharma Advanced Research Company reported revenue from operations of ₹21.99 crore (down 88.1% from Q1 FY21) and net loss of ₹61.37 crore for Q1 FY22 (Apr–Jun 2021), on a standalone basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 21.99 | 185.45 | −88.1% | 28.06 | −21.6% |
| Other income | 0.80 | 0.66 | +21.2% | 0.33 | +142.4% |
| Total income | 22.79 | 186.11 | −87.8% | 28.39 | −19.7% |
| Profit before tax | (61.37) | 56.69 | Turned loss | (56.72) | Loss widened |
| Net profit for the period | (61.37) | 56.69 | Turned loss | (56.72) | Loss widened |
| EPS, basic (₹) | (2.34) | 2.16 | Turned loss | (2.16) | Loss widened |
| Net margin (%) | -279.1 | 30.6 | -202.1 |
Standalone
- Filed with BSE
- 27 Jul 2021, 12:33 IST
- Board meeting
- 26 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE